SLC1A5 is a Key Regulator of Glutamine Metabolism and a Prognostic Marker for Aggressive Luminal Breast Cancer

Overview

Journal Sci Rep

Date 2025 Jan 22

PMID 39843491

Authors

Lutfi H Alfarsi

Rokaya El Ansari

Busra Erkan

Ali Fakroun

Madeleine L Craze

Mohammed A Aleskandarany

Kiu Wai Cheng

Ian O Ellis

Emad A Rakha

Andrew R Green

Affiliations

Soon will be listed here.

Abstract

Cancer cells exhibit altered metabolism, often relying on glutamine (Gln) for growth. Breast cancer (BC) is a heterogeneous disease with varying clinical outcomes. We investigated the role of the amino acid transporter SLC1A5 (ASCT2) and its association with BC subtypes and patient outcomes. In large BC cohorts, SLC1A5 mRNA (n = 9488) and SLC1A5 protein (n = 1274) levels were assessed and correlated their expression with clinicopathological features, molecular subtypes, and patient outcomes. In vitro SLC1A5 knockdown and inhibition studies in luminal BC cell lines (ZR-75-1 and HCC1500) were used to further explore the role of SLC1A5 in Gln metabolism. Statistical analysis was performed using chi-squared tests, ANOVA, Spearman's correlation, Kaplan-Meier analysis, and Cox regression. SLC1A5 mRNA and SLC1A5 protein expression were strongly correlated in luminal B, HER2 + and triple-negative BC (TNBC). Both high SLC1A5 mRNA and SLC1A5 protein expression were associated with larger tumour size, higher grade, and positive axillary lymph node metastases (P < 0.01). Importantly, high SLC1A5 expression correlated with poor BC-specific survival specifically in the highly proliferative luminal subtype (P < 0.001). Furthermore, SLC1A5 knockdown by siRNA or GPNA inhibition significantly reduced cell proliferation and glutamine uptake in ZR-75-1 cells. Our findings suggest SLC1A5 plays a key role in the aggressive luminal BC subtype and represents a potential therapeutic target. Further research is needed to explore SLC1A5 function in luminal BC and its association with Gln metabolism pathways.

References

Cao M, Lamichhane S, Lundgren S, Bofin A, Fjosne H, Giskeodegard G . Metabolic characterization of triple negative breast cancer. BMC Cancer. 2014; 14:941. PMC: 4295321. DOI: 10.1186/1471-2407-14-941. View

Ansari R, Craze M, Diez-Rodriguez M, Nolan C, Ellis I, Rakha E . The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes. Br J Cancer. 2018; 118(8):1115-1122. PMC: 5931111. DOI: 10.1038/s41416-018-0038-5. View

Jerjees D, Negm O, Alabdullah M, Mirza S, Alkaabi M, Hameed M . The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways. Breast Cancer Res Treat. 2015; 150(1):91-103. DOI: 10.1007/s10549-015-3308-4. View

Larriba S, Sumoy L, Ramos M, Gimenez J, Estivill X, Casals T . ATB(0)/SLC1A5 gene. Fine localisation and exclusion of association with the intestinal phenotype of cystic fibrosis. Eur J Hum Genet. 2002; 9(11):860-6. DOI: 10.1038/sj.ejhg.5200726. View

Alfarsi L, Ansari R, Craze M, Mohammed O, Masisi B, Ellis I . SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2021; 189(2):317-331. PMC: 8357718. DOI: 10.1007/s10549-021-06298-1. View

Aleskandarany M, Rakha E, Ahmed M, Powe D, Ellis I, Green A . Clinicopathologic and molecular significance of phospho-Akt expression in early invasive breast cancer. Breast Cancer Res Treat. 2010; 127(2):407-16. DOI: 10.1007/s10549-010-1012-y. View

Budczies J, Pfitzner B, Gyorffy B, Winzer K, Radke C, Dietel M . Glutamate enrichment as new diagnostic opportunity in breast cancer. Int J Cancer. 2014; 136(7):1619-28. DOI: 10.1002/ijc.29152. View

Timmerman L, Holton T, Yuneva M, Louie R, Padro M, Daemen A . Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 2013; 24(4):450-65. PMC: 3931310. DOI: 10.1016/j.ccr.2013.08.020. View

Reynolds M, Lane A, Robertson B, Kemp S, Liu Y, Hill B . Control of glutamine metabolism by the tumor suppressor Rb. Oncogene. 2013; 33(5):556-66. PMC: 3918885. DOI: 10.1038/onc.2012.635. View

10.

Gross M, Demo S, Dennison J, Chen L, Chernov-Rogan T, Goyal B . Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014; 13(4):890-901. DOI: 10.1158/1535-7163.MCT-13-0870. View

11.

Kim S, Kim D, Jung W, Koo J . Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer. Endocr Relat Cancer. 2013; 20(3):339-48. DOI: 10.1530/ERC-12-0398. View

12.

van Geldermalsen M, Wang Q, Nagarajah R, Marshall A, Thoeng A, Gao D . ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2015; 35(24):3201-8. PMC: 4914826. DOI: 10.1038/onc.2015.381. View

13.

Zhao X, Jin L, Liu Y, Liu Z, Liu Q . Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer. Ann Transl Med. 2022; 10(14):777. PMC: 9372701. DOI: 10.21037/atm-22-2620. View

14.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

15.

Kaira K, Arakawa K, Shimizu K, Oriuchi N, Nagamori S, Kanai Y . Relationship between CD147 and expression of amino acid transporters (LAT1 and ASCT2) in patients with pancreatic cancer. Am J Transl Res. 2015; 7(2):356-63. PMC: 4399098. View

16.

Yazawa T, Shimizu K, Kaira K, Nagashima T, Ohtaki Y, Atsumi J . Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma. Am J Transl Res. 2015; 7(6):1126-39. PMC: 4532745. View

17.

Abd El-Rehim D, Ball G, Pinder S, Rakha E, Paish C, Robertson J . High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer. 2005; 116(3):340-50. DOI: 10.1002/ijc.21004. View

18.

Todorova V, Kaufmann Y, Luo S, Klimberg V . Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake. Cancer Chemother Pharmacol. 2010; 67(2):285-91. DOI: 10.1007/s00280-010-1316-y. View

19.

Lancashire L, Powe D, Reis-Filho J, Rakha E, Lemetre C, Weigelt B . A validated gene expression profile for detecting clinical outcome in breast cancer using artificial neural networks. Breast Cancer Res Treat. 2009; 120(1):83-93. DOI: 10.1007/s10549-009-0378-1. View

20.

Abdel-Fatah T, Powe D, Ball G, Lopez-Garcia M, Habashy H, Green A . Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer. J Pathol. 2010; 222(4):388-99. DOI: 10.1002/path.2775. View